Abstract Search

ea0059p002 | Adrenal and steroids | SFEBES2018

11β-HSD type 1 inhibitor ameliorates metabolic disorders associated with hypercortisolemia: A clinical trial to assess its safety and efficacy in Japanese patients with refractory Cushing’s syndrome and subclinical Cushing’s syndrome

Oda Satoko , Nagata Hiromi , Ashida Kenji , Sakamoto Shohei , Uchiyama Makiko , Nagayama Ayako , Iwata Shimpei , Todaka Koji , Nakanishi Yoichi , Nomura Masatoshi

Cushings syndrome (CS) and subclinical Cushings syndrome (SCS) show poor prognosis due to hypercortisolemia, which causes metabolic disorders, such as diabetes mellitus, hypertension, dyslipidemia, and osteoporosis. Aiming to improve prognosis and develop a novel treatment for these refractory diseases, we have been constructing a patient registry of CS and SCS founded on a multicenter database at Kyushu University hospital and related facilities since 2001. CS inc...

0 shares

Endocrine Abstracts

11β-HSD type 1 inhibitor ameliorates metabolic disorders associated with hypercortisolemia: A clinical trial to assess its safety and efficacy in Japanese patients with refractory Cushing’s syndrome and subclinical Cushing’s syndrome

BiosciAbstracts